Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Dasatinib,DasaStudy001,2021,USA,MDV,350,62,45,55,27.5,32,88,12,15,35,30,20,40,30,20,10,25,35,40,18,7,4,9,5,22,48,55,TPF,DCF,Docetaxel + Carboplatin,Paclitaxel,0,0,0,25,60,40,15,45,40,65,2
Dasatinib,DasaStudy002,2022,Canada,Claim Database,420,68,48,52,28.1,28,85,15,18,32,32,18,38,32,18,12,22,38,40,20,8,5,10,6,25,50,52,TPF,5-FU + Cisplatin,Docetaxel + Carboplatin,Paclitaxel + Trastuzumab,0,0,0,28,62,42,12,48,40,70,1
Dasatinib,DasaStudy003,2023,UK,MDV,280,70,52,48,29.5,25,82,18,20,30,35,15,42,28,15,15,28,32,40,22,9,6,11,7,28,52,50,5-FU + Cisplatin,TPF,Carboplatin + Pemetrexed,Docetaxel,0,0,0,30,65,45,10,50,40,75,3
